NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
H. Lee Moffitt Cancer Center and Research Institute
Peregrine Pharmaceuticals
Peregrine Pharmaceuticals
Peregrine Pharmaceuticals